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Transcription cofactor GRIP1 differentially affects
myeloid cell–driven neuroinflammation and
response to IFN-β therapy
Sanda Mimouna1*, David A. Rollins1,2*, Gayathri Shibu1,2, Bowranigan Tharmalingam1, Dinesh K. Deochand1, Xi Chen1,2, David Oliver1,
Yurii Chinenov1, and Inez Rogatsky1,2
Macrophages (MV) and microglia (MG) are critical in the pathogenesis of multiple sclerosis (MS) and its mouse model,
experimental autoimmune encephalomyelitis (EAE). Glucocorticoids (GCs) and interferon β (IFN-β) are frontline treatments for
MS, and disrupting each pathway in mice aggravates EAE. Glucocorticoid receptor–interacting protein 1 (GRIP1) facilitates
both GR and type I IFN transcriptional actions; hence, we evaluated the role of GRIP1 in neuroinflammation. Surprisingly,
myeloid cell–specific loss of GRIP1 dramatically reduced EAE severity, immune cell infiltration of the CNS, and MG activation
and demyelination specifically during the neuroinflammatory phase of the disease, yet also blunted therapeutic properties of
IFN-β. MV/MG transcriptome analyses at the bulk and single-cell levels revealed that GRIP1 deletion attenuated nuclear
receptor, inflammatory and, interestingly, type I IFN pathways and promoted the persistence of a homeostatic MG signature.
Together, these results uncover the multifaceted function of type I IFN in MS/EAE pathogenesis and therapy, and an
unexpectedly permissive role of myeloid cell GRIP1 in neuroinflammation.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease that
affects the central nervous system (CNS) and whose etiology
remains unknown (Bishop and Rumrill, 2015; Dendrou et al.,
2015; Lassmann, 2011). Clinically, four types of MS have been
described: primary progressive MS; secondary progressive
MS; progressive relapsing; and, the most common, relapsing-
remitting MS (RRMS; Milo and Miller, 2014). For all types, au-
toimmune demyelination is the hallmark of the disease, which
prompted much work dissecting the roles of T cells (Jäger et al.,
2009; Kaskow and Baecher-Allan, 2018; Liu et al., 2008;
McGinley et al., 2018; Merrill et al., 1992) and B cells (Negron
et al., 2019; Staun-Ram and Miller, 2017; Weber et al., 2010) in
MS. However, recent accumulating evidence demonstrates the
pivotal role of myeloid cells such as microglia (MG) in MS
pathogenesis (Croxford et al., 2015; Mahad and Ransohoff, 2003;
Mishra and Yong, 2016; Sominsky et al., 2018; Yamasaki, 2014).
MG are CNS-resident specialized macrophage (MV)-like cells
with a ramified morphology and motile processes that enable
MG to migrate throughout the CNS, constantly surveying the
environment and responding accordingly if any change is de-
tected. In healthy conditions, they ensure brain homeostasis by
pruning neurons, clearing debris, and providing neurotrophic
factors during development and adult life (Hagemeyer et al.,
2017; Kierdorf and Prinz, 2017). MG and MV share a common
erythromyeloid progenitor, but they part ways very early in
development (embryonic day 9.5 [E9.5]), when MGmigrate into
the fetal brain, where they maintain their pool through self-
renewal (Ginhoux et al., 2010; Kierdorf et al., 2013). In con-
trast, MV rely on bone marrow (BM)–derived precursors for
renewal and are able to circulate into the blood as monocytes or
reside in tissues, depending on their role and immunological
state (Goldmann et al., 2016). Both cell types display high plas-
ticity (Holtman et al., 2017; Italiani and Boraschi, 2014; Murray,
2017; Shemer et al., 2015) and can have similar roles, especially
during inflammation. In disease, such asMS, together with CNS-
infiltrating MV, MG shape the immune responses through
antigen presentation, phagocytosis of myelin, and cytokine se-
cretion (Almolda et al., 2011; Fourgeaud et al., 2016; Franco and
Fernández-Suárez, 2015). These functions place MG and MV as
central effectors of neuroinflammation, but their specific and
potentially divergent contribution to MS pathogenesis remains
poorly defined.
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Recent genomic and transcriptomic tools made it possible to
better characterize the myeloid cells of the CNS, and especially
MG, by building the “microgliome” (Gosselin et al., 2017;
Holtman et al., 2017; Sousa et al., 2017). An increasing number of
studies are investigating the transcriptional signatures of MG
and MV at homeostasis and during MS or experimental auto-
immune encephalomyelitis (EAE), a commonly used mouse
model for RRMS (Holtman et al., 2017; Sevastou et al., 2016; van
der Poel et al., 2019). These studies showed that, apart from the
surface proteins shared by these two cell types (e.g., Cd45,
Cd11b), certain markers are MG specific (Tmem119/Sall1) or MV
specific (Ccr2), illustrating not only distinct ontology of these
cells but also their different responses depending on the local
environment (Bennett et al., 2016; Buttgereit et al., 2016; Gu
et al., 2016; Koeniger and Kuerten, 2017). Nevertheless, during
neuroinflammation, MV infiltrate the CNS together with the
bulk of immune cells and, along with MG, become activated,
which shifts the transcriptomic makeup and, consequently the
repertoire of molecules expressed on their surface, making these
cells harder to distinguish from each other (Greter et al., 2015;
Prinz et al., 2011).
There is no cure for MS; however, glucocorticoid (GC) hor-
mones and type I IFN (specifically, IFN-β) are used to alleviate
MS symptoms (Goodin, 2014; Vosoughi and Freedman, 2010;
Wingerchuk and Carter, 2014). GC hormones are potent anti-
inflammatory drugs that are also essential for preventing irre-
versible neuronal damage duringMS flares (Goodin, 2014; Smets
et al., 2017). They act through the GC receptor (GR), a ligand-
dependent transcription factor that localizes to specific genomic
binding sites and activates anti-inflammatory genes (e.g., Dusp1,
Tsc22d3) or, by tethering to nonreceptor transcription factors
AP1 and NF-κB, represses proinflammatory ones (e.g., Tnf, Il1b;
Nissen and Yamamoto, 2000; Sacta et al., 2018; Uhlenhaut et al.,
2013). Interestingly, a unique p160/NCoA GR coregulator—
GR–interacting protein 1 (GRIP1/NCoA2/TIF2)—facilitates both
GR-mediated activation and repression (Chinenov et al., 2012;
Lee et al., 2002; Rollins et al., 2017). In fact, loss of GRIP1 in
myeloid cells such as MV leads to a dramatic derepression of
numerous inflammatory mediators, which in vivo sensitizes
mice to acute LPS-induced sepsis and chronic high-fat diet–
induced metabolic inflammation (Chinenov et al., 2012; Coppo
et al., 2016; Rollins et al., 2017).
IFN-β is prescribed to RRMS patients to delay relapses and
disease progression (Bermel and Rudick, 2007). The type I IFN
pathway is triggered upon TLR3 activation that, through a series
of adapter proteins, leads to activating phosphorylation of IFN-
regulatory factors 3/7 (IRF3/7) that bind IFN-stimulated re-
sponse elements and initiate the IFN-β gene transcription.
Newly produced IFN-β acts in a para- and autocrine manner via
the IFN-α/β receptor (IFNAR) at the cell surface, inducing the
second wave of signaling through JAK/STAT phosphorylation
and assembly of the ISGF3 (STAT1/STAT2/IRF9) transcription
complex that binds IFN-stimulated response elements and ac-
tivates numerous IFN-stimulated genes (ISGs; Chen et al., 2017).
Studies in mice showed that a whole-body KO of IFN-β worsens
EAE (Teige et al., 2003) and that conditional IFNAR-KO in my-
eloid cells or GR-KO in hematopoietic cells also leads to more
severe disease and enhanced lethality, lending genetic support to
therapeutic efficacy of IFN-β in EAE and MS (Prinz et al., 2008;
Wüst et al., 2008). The protective role of IFN-β in MS, however,
is puzzling in light of the well-established pathogenic role of
type I IFN in other autoimmune diseases, such as systemic lupus
erythematosus, Sjögren syndrome, and neuromyelitis optica, to
name a few (Axtell et al., 2011; Crow, 2014). The exact mecha-
nisms underlying a beneficial function of IFN-β in MS remain
obscure. Unexpectedly, we discovered that GRIP1 physically
interacts with several members of the IRF family and potentiates
type I IFN signaling in MV in conjunction with IRFs 3, 7, and 9
(Flammer et al., 2010; Reily et al., 2006). The contribution of
GRIP1 to the type I IFN network in vivo has never been assessed.
Given that MV GRIP1 cooperated with both GRs and IRFs,
transcription factors that reportedly mediate neuroprotection in
MS, we sought to assess the function of this coregulator during
neuroinflammation. Here, using mice conditionally lacking
GRIP1 in myeloid cells, we describe an unexpected impact
of GRIP1 on the neuroinflammatory phase of EAE, potentially
pointing to different roles it plays in MG versus peripheral MV.
We analyze transcriptomic changes that occur in the myeloid
compartment of the CNS at homeostasis and during EAE at the
bulk and single-cell levels. Finally, we present data on GRIP1
driving the effect of a frontline treatment of MS in mice
with EAE.
Results
GRIP1 regulates the inflammatory transcriptome in P0 MG
in vitro
As MG plays a central role in both MS and EAE, we first es-
tablished a cell culture system to study and manipulate these
cells ex vivo. We isolated primary MG from P0 neonatal mice
and expanded mixed glial cultures of MG on the monolayer of
astrocytes (see Materials and methods). MG were then purified
on CD11b-coated beads and treated with proinflammatory LPS
for 2 h in the absence or presence of either dexamethasone (Dex;
a synthetic GC) or IFN-β, the two compounds clinically used to
alleviate neuroinflammation in MS, followed by expression
profiling using RNA sequencing (RNAseq). Of 963 LPS-regulated
genes, 553 were induced; of those, 163 were downregulated by
Dex and 115 were downregulated by IFN-β (Fig. S1 A, top). In-
terestingly, only a small group of 20 genes overlapped in the
two datasets; that is, theywere repressed by both Dex and IFN-β,
but those encoding key proinflammatory cytokines Tnf, Il1a,
Il1b, and Il12b were among them (Fig. S1 A, top right, under-
lined). We have previously established that GRIP1 mediates anti-
inflammatory actions of GR in BM-derived primary MV
(BMMV) by potentiating both activation of anti-inflammatory
genes (e.g., Tsc22d3, Dusp1) and repression of proinflammatory
ones such as Tnf, Il1a, and Il1b (Rollins et al., 2017). To examine
the impact of GRIP1 loss in MG, we performed RNAseq analysis
on the P0 MG derived in culture from the LysMCre+/+;GRIP1fl/fl
mouse strain (referred to as GRIP1-cKO) lacking GRIP1 in the
myeloid lineage (Fig. 1 A and Fig. S1 B). From 1,403 LPS-
responsive genes, 854 were induced, and approximately one-
half of them (430) were repressed by Dex; yet, only 96 were
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downregulated by IFN-β (Fig. S1 A, bottom). As a result, the
number of genes repressed by both Dex and IFN-β in GRIP1-cKO
MG was down to 11 and no longer included Tnf and Il12b (Fig. S1
A, bottom right, underlined).
A quantitative assessment of the consequences of GRIP1 de-
letion on repression of proinflammatory genes by GR revealed
that GRIP1 loss in MG modestly attenuated repression of Nlrp3
(Fig. S1 B). In addition, a typical ISG, Ifit1, was less IFN-β re-
sponsive in GRIP1-cKO MG than WT (Fig. S1 B). Overall, the
impact of GRIP1 deletion on representative genes of these two
classes ex vivo resembled that seen in MV. Of note, the effect of
type I IFN on LPS-induced genes and the potential role of GRIP1
in this context have not been previously evaluated in any
cell type.
Myeloid cell–specific deletion of GRIP1 in vivo attenuates EAE
Given extensive evidence for the transcriptional makeup of MG
being determined by the local CNS environment (Gosselin et al.,
2017), we reasoned that evaluating MG responses following
3-wk differentiation and expansion in culture may underesti-
mate the impact of treatments, of GRIP1 deletion, or both on MG
biology. Thus, to assess the role of GRIP1 in MG in vivo, we in-
duced EAE in WT and GRIP1-cKO mice and monitored disease
progression (seeMaterials and methods). In stark contrast to the
endotoxin shock model, GRIP1-cKO mice displayed dramatically
lower EAE scores than WT, which correlated with less weight
loss and better survival with no significant difference in
symptom onset time or incidence between groups (Fig. 1 B).
Notably, there were no sex-specific differences in EAE severity
between WT and GRIP1-cKO mice; that is, male and female
GRIP1-cKO mice were similarly protected (Fig. 1 B). Importantly,
the EAE-resistant phenotype of GRIP1-cKOwas evident, regardless
of whether the LysM-expressing (LysMCre+/+;GRIPwt/wt) or LysM-
nonexpressing (LysMCre−/−;GRIP1fl/fl) strain was used as a WT
control (Fig. S2 A). Further departing from the “cytokine storm”
phenotype of the GRIP1-cKO in the endotoxin shock model
(Chinenov et al., 2012; Rollins et al., 2017), the levels of signature T
helper type 1 cell (Th1) cytokines TNF, IFN-γ, and IL-6 during EAE
were reduced in the serum of GRIP1-cKO compared to WT mice,
corresponding to their less severe systemic inflammatory re-
sponse (Fig. 1 C), with no difference between genotypes seen at
homeostasis (Fig. S2 B, left).
Histological signs of MS and EAE are leukocyte infiltration,
white matter damage, and demyelination of the CNS (Gibson-
Corley et al., 2016; Pyka-Fosciak et al., 2018). We assessed these
parameters in cervical, lumbar, and thoracic spinal cord seg-
ments from WT and GRIP1-cKO mice at homeostasis (Fig. S2 B,
right) and during EAE (Fig. 2). H&E staining revealed a dra-
matically attenuated leukocyte infiltration in the CNS of GRIP1-
cKO relative to WT, which correlated with a reduced number of
infiltrating T lymphocytes (Fig. 2, A and B); Luxol fast blue (LFB)
staining of myelin showed areas of local demyelination in the
CNS of WT (Fig. 2, A and B). Functional states of MG can be
defined morphologically; at homeostasis, MG are ramified and
exhibit highly branched processes, whereas during inflamma-
tion, activatedMG retract their processes and enlarge cell bodies
due to organelle buildup and increased metabolic activity
Figure 1. Myeloid cell–specific GRIP1 deletion ameliorates EAE.
(A) GRIP1 Western blots of BMMV, MG expanded in vitro from P0 pups,
spleen CD4+ T cells, dorsal root ganglia (DRG) neurons, and astrocytes
from WT and GRIP1-cKO mice; heat shock protein 90 (HSP90) is the
loading control. Molecular weight ladder (kD) is shown on the right.
(B) EAE progression in WT and GRIP1-cKO mice. Clinical scores (upper
left) were evaluated at indicated DPI and plotted as the mean ± SEM of
individual male (M) and female (F) mice (WT = 27; GRIP1-cKO = 22) from
three independent experiments (Kruskal-Wallis test with Dunn’s multiple
comparisons test). Mice were weighed at DPI0 and DPI20, and the frac-
tion lost was compared (upper right; unpaired two-tailed Student’s t test).
Mice at clinical scores ≥8 were killed; the Kaplan-Meier estimator was
used to analyze survival (lower left; Mantel-Cox test). Disease incidence
(%) and DPI of symptom onset in WT and GRIP1-cKO mice are shown
(lower right). *, P < 0.05; **, P < 0.01. (C) At DPI20, blood was collected by
cardiac puncture, and inflammatory cytokine levels were measured using
CBA (WT = 10; GRIP1-cKO = 12 from two independent experiments; un-
paired two-tailed Student’s t test). *, P < 0.05; **, P < 0.01.
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(Sominsky et al., 2018). Fig. 2, A and B, demonstrate Iba-
1–positive MG located in the parenchyma of WT and GRIP1-
cKO spinal cords with visibly enlarged, amoeboid-like MG in
the WT compared with ramified, multiprocessed MG in the
GRIP1-cKO. No histological differences between WT and GRIP1-
cKO spinal cords were observed at homeostasis (Fig. S2 B, right).
Given that EAE is driven by both CNS-resident and CNS-
infiltrating peripheral immune cells, we profiled the immune
cell populations in the spinal cords of WT and GRIP1-cKO mice
by flow cytometry at homeostasis (Fig. S2 B, middle) and fol-
lowing EAE induction (Fig. 2 C). Immune cells were sorted using
common lineage-specific surface markers (see gating strategy in
Fig. S2 C; Greter et al., 2015). We differentiated MG fromMV on
the basis of expression level of CD45 (MG, CD45low; MV,
CD45high; Fig. S2 C) as described previously (Rangaraju et al.,
2018; Sedgwick et al., 1991). Consistent with clinical scores and
histopathology, although no difference in the CNS-resident im-
mune cell number was seen between WT and GRIP1-cKO at
homeostasis (Fig. S2 B, middle), during EAE, GRIP1-cKO accu-
mulated fewer total leukocytes (CD45+), T lymphocytes (CD3+),
and myeloid and B cells (CD11b+) in their CNS in counts and in
percentage of initial population than did WT mice. Importantly,
the strikingly lower number of infiltrating MV in the CNS of
GRIP1-cKO mice resulted in the apparently higher fraction of
“less diluted” resident MG among the F4/80+CD11+ cells (Fig. 2
C). Together, these results demonstrate that, contrary to its
Figure 2. Histological signs of EAE are at-
tenuated in spinal cords of GRIP1-cKO mice.
(A) Spinal cord lumbar sections from WT and
GRIP1-cKO mice at DPI20 from three inde-
pendent experiments were analyzed by H&E
staining for inflammatory foci (rectangle), LFB
staining for myelin, and immunohistochemistry
for CD3+ infiltrating T cells (arrowheads) and Iba-
1+ MG (in parenchyma). Scale bars are 100 µm.
(B) Quantification of slides from A for inflam-
mation (percentage of inflammatory pockets),
demyelination (LFB-stained myelin/area), CD3+
cells, and a number of ramified (with processes)
and amoeboid-like (round-shaped with retracted
processes) MG was performed as described in
the Materials and methods section (unpaired
two-tailed Student’s t test). **, P < 0.01; ***, P <
0.001. (C) FACS analysis of leukocytes isolated
from spinal cords of WT or GRIP1-cKO mice at
DPI20 is plotted as a percentage of gated parent
population and total counts (Mann-Whitney U
test). *, P < 0.05; **, P < 0.01.
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inhibitory actions in other models of MV-driven inflammation,
myeloid cell GRIP1 plays a permissive role in the onset and/or
progression of EAE.
GRIP1 facilitates the neuroinflammatory “effector” stage of
EAE
To determine the hallmarks of EAE pathogenesis that were
sensitive to GRIP1 deletion, we evaluated the expression of in-
flammatory mediators in the CNS of control and EAE WT and
GRIP1-cKO mice. Although no genotypic differences were ob-
served in the level of any transcripts measured at homeostasis,
therewas a significant accumulation of proinflammatory Tnf but
not anti-inflammatory Il10 during EAE in the brains and spinal
cords of WT mice, and this effect was greatly attenuated in
GRIP1-cKO (Fig. 3 A and Fig. S3 A, top). Unexpectedly, several
established components of the type I IFN network (Irf1, Irf7, Isg15,
and Ifit1) were dramatically upregulated during EAE specifically
in the WT CNS (Fig. 3 A and Fig. S3 A). Even though this result
was consistent with the requirement for GRIP1 in the IFN
pathway, a pronounced IFN signature in mice with more severe
pathology argues against type I IFN serving a solely protective
role in EAE/MS.
In principle, GRIP1 either can act on the periphery to facili-
tate an immune response and generation of myelin-reactive
autoimmune T cells during the inductive phase or, alterna-
tively, can contribute to myeloid cell–driven neuroinflammation
during the effector phase. To assess the potential contribution of
GRIP1 to each stage of the disease, first, we harvested peripheral
immune organs—the spleens and draining LNs (dLNs)—from
WT and GRIP1-cKO mice with or without EAE and evaluated
their gross morphology. Although the size of the spleens in-
creased significantly during EAE compared to that at homeo-
stasis, there was no genotypic difference in the size of the
spleens, number of splenocytes, or number of CD4+ T cells (Fig. 3
B). In addition, flow cytometry performed on the spleens of WT
and GRIP1-cKO mice with EAE revealed similar percentages of
leukocytes (CD45+), lymphocytes (CD3+), CD4+ or CD8+ T cells,
B220+ B cells, and CD11b+ myeloid cells in the two genotypes
(Fig. 3 C).
We next isolated CD4+ T cells from spleens and dLNs of WT
and GRIP1-cKOmice at day 7 postimmunization (DPI7) or DPI20,
restimulated them with myelin oligodendrocyte glycoprotein
(MOG) peptide in vitro for 72 h, and analyzed the production of
Th1 and Th17 cytokines implicated inMS pathology as well as the
EAEmodel. Of those, we observed slightly reduced levels of IFN-
γ produced by CD4+ T cells from GRIP1-cKO mice at DPI7 only,
whereas the levels of TNF, MCP1, and IL-17A were identical in
the two genotypes at both time points (Fig. 3 D). Interestingly, at
DPI7, restimulated CD4+ T cells isolated fromWTmice produced
more IL-4 and IL-10 than the ones from GRIP1-cKO mice, but
these differences were abrogated by DPI20 (Fig. S3 B). This re-
sult does not definitively establish the T cell subtype mediating
EAE in our model, but it illustrates a transiently attenuated Th2
CD4+ T cell signature in the GRIP1-cKO mice compared to
WT mice.
To definitively determine the stage of EAE during which
GRIP1 contributes to disease, we used a passive EAE model in
which the inductive and effector phases are uncoupled from
each other. Following EAE induction in WT female donor mice,
CD4+ T cells were collected from their spleens and dLNs at
DPI10, Th1 polarized in vitro (see Materials and methods), and
injected into recipient WT and GRIP1-cKO mice along with
pertussis toxin (PTX). Despite expected lower clinical scores in
this passive model, WTmice still developedmore severe disease,
which, strikingly, occurred earlier and in a greater number of
animals than it did in the GRIP1-cKO mice (Fig. 4 A). Consis-
tently, GRIP1-cKO mice lost less weight and displayed less im-
mune cell infiltration of the CNS (Fig. 4, A and B). Together,
these results demonstrate that myeloid cell GRIP1 facilitates the
effector neuroinflammatory phase of EAE.
Transcriptomic consequences of myeloid cell–specific GRIP1
deletion in the CNS
GRIP1 is a broadly acting transcriptional coregulator whose role
inMS/EAE or inMG at any state has never been investigated. To
begin to identify the GRIP1-dependent transcriptome changes
leading to neuroinflammation, we performed bulk RNAseq
analysis on CD45+Cd11b+ myeloid cells isolated from spinal cords
of WT and GRIP1-cKO mice. Consistent with a lack of overt
phenotype in our conditional GRIP1-deficient mice (Coppo et al.,
2016; Rollins et al., 2017), at homeostasis, a CD45+Cd11b+ CNS
myeloid cell population composed principally of MG displayed
no significant transcriptomic differences between WT and
GRIP1-cKOmice (Fig. 5 A, upper panel; GRIP1 deletion efficiency
is shown on the right as normalized read counts across “floxed”
exon 11 of the Ncoa2 gene). In contrast, more heterogeneous
activated CD45+Cd11b+ cells during EAE (Fig. S2 C and Fig. 2 C)
presented distinct transcriptomic signatures in WT versus
GRIP1-cKO mice. Indeed, genes upregulated in WT (Fig. 5 A,
lower panel, and Fig. 5 B), such as chemokines and chemokine
receptors (Ccl22, Ccr7), antigen presentation molecule (H2-q10),
components of complement (C3, C1ra), and type I IFN (Trim12c,
Oas3) pathways, are indicative of inflammation and EAE path-
ogenesis (Belikan et al., 2018; Salter and Stevens, 2017; Scheu
et al., 2017). Interestingly, a pool of genes downregulated in WT
mice during EAE but persisting in GRIP1-cKO mice (e.g., Gpr34,
P2ry12; Fig. 5 A, lower panel, and Fig. 5 B) are homeostatic genes
referred to as the MG “sensome” (Hickman et al., 2013), which
controls chemotaxis and tissue repair (Lou et al., 2016).
To identify physiologically relevant pathways differentially
active in myeloid cells from WT and GRIP1-cKO spinal cords
during EAE, we performed quantitative set analysis of gene
expression (QuSAGE; Yaari et al., 2013), a gene set enrichment
analysis–like Bayesian method that provides better accounts for
intergene correlations than classic gene set enrichment analysis.
QuSAGE determines pathway-wide expression (pathway activ-
ity) by combining probability density functions for individual
gene expression using numerical convolution. Several pathways
were expressed at higher levels in the WT CNS myeloid cells,
including NODE-like receptor signaling pathways (Kyoto Ency-
clopedia of Genes and Genomes) and a nuclear receptor tran-
scription pathway (REACTOME), including Nr4a2 (Nurr1) and
Nr4a3 (Nor-1; Fig. 5 C). Remarkably, several key genes of the IFN
axis (IFN signaling pathway [REACTOME]), including Irf4, Irf1,
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Ifng, Ifitm1, Gbp5, and Oas3, were also expressed at higher levels
in the WT (Fig. 5 C), in accord with whole-brain and spinal cord
quantitative PCR (qPCR) data (Fig. 3 A and Fig. S5 A) and with a
demonstrated coactivator role for GRIP1 in type I IFN network in
MV (Flammer et al., 2010; Reily et al., 2006). Collectively, these
data demonstrate a failure to upregulate inflammatory and type
I IFN pathways and persistence of homeostatic signature in
GRIP1-cKO myeloid cells; however, it could potentially stem
from the role of GRIP1 in MG, MV, or both.
To dissect the contribution of resident versus infiltrating
myeloid cells to EAE pathogenesis, we performed single-cell
RNAseq (scRNAseq) analysis of all myeloid CD45+CD11b+ cells
from WT and GRIP1-cKO spinal cords at the peak of EAE
(DPI20). After filtering out low-quality barcodes (see Materials
and methods), we analyzed 20,376 cells (6,427 WT and 11,949
cKO) expressing 11,093 genes. Automated cell type assignment
with singleR yielded four major clusters—“monocytes,” “MV,”
“dendritic cells,” and “neutrophils” (Fig. 6 A and Table S1)—and
a large number of minor clusters composed predominately
of lymphoid cell impurities that were collected during the
cell sorting and had the same location in uniform manifold
approximation and projection (UMAP) coordinates (Fig. 6 A).
Because of an unbalanced group size, we performed a boot-
strapping analysis to determine the associations between gen-
otype and singleR cell types. We counted cell types of 2,000
cells that were sampled with the replacement from each geno-
type with 500 repeats (Fig. 6 B and Fig. S4 A). This analysis
indicated that singleR monocytes and neutrophils were more
Figure 3. GRIP1-cKO mice develop less brain
inflammation than WT mice but a similar
peripheral T cell response in vitro. (A) Brains
were harvested from control (WT = 5; GRIP1-
cKO = 4) and EAE DPI20 (WT = 6; GRIP1-cKO =
6) mice from two independent experiments, and
total RNA was extracted. Relative expression of
the indicated genes was evaluated by RT-qPCR,
normalized to that of the Actb housekeeping
gene, and expressed relative to WT control (= 1;
two-way ANOVA with Tukey’s multiple com-
parisons test). *, P < 0.05; **, P < 0.01; ****, P <
0.0005. ns, nonsignificant. (B) Spleens were
collected from WT and GRIP1-cKO control mice
(n = 5 each) and EAE DPI20 mice (n = 7 each)
from one experiment, and their weights (in mg)
were compared (Kruskal-Wallis test with Dunn’s
multiple comparisons test; *, P < 0.05). Numbers
of splenocytes and CD4+ cells isolated from
spleens and dLNs were quantified by FACS
analysis. (C) FACS analysis of leukocytes isolated
from spleens of WT and GRIP1-cKO mice at
DPI20 is plotted as a percentage of the gated
parent population. (D) Spleens were collected
from WT and GRIP1-cKO mice at DPI7 (WT = 10;
GRIP1-cKO = 9 from two independent experi-
ments) and DPI20 (n = 5 each from one experi-
ment). CD4+ T cells were isolated and
restimulated with MOG35–55 in vitro, and the
indicated Th1 and Th17 secreted cytokines were
quantified using CBA (unpaired two-tailed Stu-
dent’s t test). *, P < 0.05.
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common in the cKO, whereas MV were overrepresented in the
WT. There was a substantial overlap between singleR cell types,
suggesting either the presence of cell subpopulations or differ-
ent differentiation/activation states. To separate these states, we
performed Louvain graph–based community clustering that
yielded nine clusters (Fig. 6 C and Table S2). Cluster 8 corre-
sponded to singleR lymphoid cell–enriched group (Fig. 6 A;
“Others,” “T cells”), whereas cluster 6 was highly enriched with
canonical neutrophilic markers (Fig. 6, A, D, and E). Cluster 3 is
enriched in proliferation markers (Fig. 6 E, Fig. S4 B, and Table
S4). Slingshot trajectory analyses anchored on cluster 3 (see
Materials and methods) identified two main trajectories (3-5-9-
7-1 and 3-5-9-2-4-6) bifurcating at cluster 9 (Fig. 6 C and Fig. S4
C). The analysis of genes differentially expressed along trajec-
tories suggested that the 3-5-9-7-1 trajectory likely corresponds
to monocyte-to-MV transitions. Conversely, clusters 2-4-6 ex-
hibit an increasing gradient of expression of neutrophilic
markers (Fig. 6 E; S100a8, S100a9), suggesting that clusters 4 and
2 contain a decreasing admixture of neutrophils from cluster 6.
Cluster 3 expresses monocytic markers at high levels (Fig. 6 F;
Ly6c2, F13a1, Stmn1) and activated MV/MG markers at low levels
(Fig. 6, F and G; Cd74, Fth1, Fcgr2b, H2-Aa, Il1b) that reciprocally
change along the trajectories. MV-like clusters (1, 7, and 2)
contain either different proportions of MV/MG, different
activation states, or an admixture of other cell types (e.g.,
oligodendrocyte precursors; Table S3). Although expression
distributions for activated MV/MG markers are broadly compa-
rable in these clusters (Fig. S4 D), differential expression analysis
between WT and cKO stratified by Louvain clusters revealed that
clusters 1, 7, 2, and 4 expressed markers of homeostatic MG at
higher levels in the cells from cKO mice (Fig. 6 H, Fig. S4 E, and
Table S5; Sparc, Siglech, Olfml3, and Tmem119). Cluster 2 contained
the largest percentage of cells expressing homeostatic MG mark-
ers. Conversely, many markers of activated inflammatory MV
were upregulated in these clusters in the WT cells including Il1a,
Il1r2, Il7r, Ifng, Ctla2s, and Nos2 (Fig. 6 I and Table S5).
GRIP1 mediates the therapeutic effect of IFN-β
GCs and IFN-β are a standard of care for patients with RRMS.
Consistently, genetic deletion of IFN-β or GR in mice increases
EAE severity, whereas exogenous administration of GCs or IFN-β
prevents relapses and ameliorates disease symptoms (Goodin,
2014; Vosoughi and Freedman, 2010; Wingerchuk and Carter,
2014). Given that GRIP1 is a cofactor for both GR and IRFs, the
effectors of GC and type I IFN signaling, respectively, we ex-
amined whether myeloid cell–specific GRIP1 deletion impacts
therapeutic potency of these agents in our mice.
Both Dex (50–100 mg/kg; Fig. S5 A) and recombinant IFN-β
(5,000–10,000 U; Fig. 7 A) reduced clinical scores of EAE in WT
mice in a dose-dependent manner. Next, WT and GRIP1-cKO
mice were administered PBS vehicle, 50 mg/kg Dex, or 10,000
U of IFN-β per mouse, doses that proved effective inWTmice, at
Figure 4. GRIP1 contributes to the neuroinflammatory phase of EAE. (A) Passive EAE was induced in WT and GRIP1-cKO mice (n = 13 each from two
independent experiments), and clinical scores (left) were measured and plotted daily as mean ± SEM (Mann-Whitney U test). The fraction of weight lost
between days post-transfer (DPT) 0 and 40 (middle) was compared using an unpaired two-tailed Student’s t test. The incidence of disease (%) is shown; time of
symptom onset (right) was compared using the Mann-Whitney test. *, P < 0.05; **, P < 0.01. (B) FACS analysis of leukocytes isolated from spinal cords of five
WT and four GRIP1-cKO mice (two independent experiments) at DPT40 is plotted as a percentage of the gated parent population and total counts (unpaired
two-tailed Student’s t test). *, P < 0.05.
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symptom onset (clinical score, 2.0), i.p. daily for 10 d. Compared
with PBS-treated controls, Dex therapy fully reversed EAE
progression, including clinical scores, weight loss, andmortality,
in both genotypes, indicating that GRIP1 did not mediate the
therapeutic effect of Dex in this model (Fig. S5 B). Intriguingly,
IFN-β treatment that dramatically reduced clinical scores,
weight loss, and lethality of WT mice failed to elicit any im-
provement in the GRIP1-cKO mice (Fig. 7 B), demonstrating that
myeloid cell GRIP1 was required for IFN-β efficacy in the
neuroinflammation model.
Figure 5. Transcriptomic profiling of myeloid cells from WT and GRIP1-cKO mice during homeostasis and EAE. (A) Myeloid gene expression was
modeled as batch-corrected averages of gene expression in MV (CD45high; n = 2–4) and MG (CD45low; n = 3). Top left: Volcano plot shows differentially
expressed genes (red) in WT versus GRIP1-cKO (n = 3) MG from homeostatic mice (log2 fold change (log2FC) = 1; unadjusted P value = 0.01). Top right: Library
size-normalized read counts in WT and GRIP1-cKO mice that mapped to Ncoa2 (GRIP1) exon 11 deleted by the Ncoa2 targeting construct (Gehin et al., 2002; n = 3).
Bottom: Volcano plot shows differentially expressed genes in CD45+Cd11b+ activated myeloid cells isolated from spinal cords of WT and GRIP1-cKO mice with EAE
(n = 7 and 5, respectively; log2FC = 1; unadjusted P = 0.05). Selected genes upregulated in EAE WT (WT > cKO) are shown on the right and highlighted in colors
corresponding to their functional groups (boxed in lower right). Genes with higher expression in EAE GRIP1-cKO (cKO >WT) are shown on the left, and seven genes
highlighted in brown represent the homeostatic MG “sensome.” (B) The RNAseq expression levels of select genes from A inWT and GRIP1-cKO homeostatic and EAE
mice. (C)QuSAGE of differentially expressed genes fromWT and GRIP1-cKOmicewith EAE. Differentially expressed pathways (unadjusted P < 0.01) fromMsigDB C2
set (Broad Institute) are shown. The size of the circles is proportional to the number of genes in the pathway, and the color is proportional to the P value. Genes for
the nuclear receptor transcription pathway (middle) and IFN signaling (bottom) from the REACTOME database are plotted as logFC ± SD and ordered by the logFC.
KEGG, Kyoto Encyclopedia of Genes and Genomes.
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Discussion
The role of GRIP1 in neuroinflammation
MS is a complex disease involving an interplay between innate
and adaptive immune cells in the periphery and in the CNS.
Notably, myeloid cells (MG and MV) play a dual role in
the pathogenesis: on the one hand, they promote neuro-
inflammation through antigen presentation, cytokine and
chemokine secretion, and active demyelination; on the other,
Figure 6. scRNAseq of spinal cord myeloid cells isolated from WT and GRIP1-cKO mice at EAE DPI20. (A) singleR automated cell type assignment for
20,376 spinal cord–derived myeloid cells. (B) Bootstrapping analysis (see Materials and methods) of singleR cell type (from A) distribution, stratified by
genotype: WT = blue; GRIP1-cKO = red. (C) Louvain clustering results and singleR trajectory inference for 20,376 spinal cord–derived myeloid cells mapped
onto a UMAP plot. (D) Expression of neutrophilic markers, stratified by Louvain clusters. The color of expression profiles corresponds to Louvain clusters in C.
(E) Bubble plot of top three cluster-specific markers (from C), with the circle size representing the percentage of expressing cells and the color corresponding
to logUMI. (F and G) Expression of select genes along the (F) 3–5-9-7-1 (C, blue line) and (G) 3–5-9-2-4-6 (C, black line) trajectories. The color of expression
profiles corresponds to Louvain clusters in C. (H and I) Expression of homeostatic MG (H) or inflammatory (I) markers mapped onto a UMAP plot, stratified by
genotypes. DC, dendritic cells.
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they help resolve it by clearing debris, secreting neurotrophic
factors, and facilitating tissue repair (Herz et al., 2017). This
high functional plasticity relies on precise environment-
dependent transcriptomic reprogramming. Thus, identifying
potential regulators that mediate each process is mandatory for
understanding how each cell type contributes to or counteracts
disease. Here, we propose that GRIP1 is an as yet unappreciated
transcriptional coregulator driving myeloid cell–dependent
neuroinflammation.
We show that mice lacking GRIP1 in myeloid cells had lower
clinical scores that correlated with diminished immune cell in-
filtration and a reduced proinflammatory signature in myeloid
cells of the CNS in vivo. This phenotype was unexpected, given
well-documented anti-inflammatory actions of GRIP1 in MV.
However, those studies focused on peripheral MV in the peri-
toneum or metabolic tissues, whereas CNS MV/MG function in
a unique environment and are exposed to myelin debris, other
glial cells including astrocytes, and neurons, each potentially
impacting GRIP1 behavior. A lack of CNS-specific environmental
inputs may also account for the peripheral MV-like responses to
GRIP1 deletion in our in vitro differentiated P0 MG in culture. A
tissue-specific transcriptional signature of specialized human
andmouse MV, such as MG, is reportedly “erased” ex vivo fairly
rapidly as they dedifferentiate into a more “generic”myeloid cell
(Gosselin et al., 2017). Moving forward, it will be critical to de-
velop alternative methods for MG culture that do not involve
extended expansion protocols.
Importantly, the role of GRIP1 in MG has not been studied
and could in principle be opposite that in MV. Indeed, the re-
ciprocal functions in MV versus MG in EAE pathogenesis have
been shown previously for TNFR2. Specifically, TNFR2 ablation
in MG induced an early-onset disease with increased leukocyte
infiltration and T cell activation and demyelination, whereas its
depletion in monocytes/MV suppressed EAE, impaired T cell
activation, and reduced demyelination (Gao et al., 2017). Perhaps
GRIP1 could potentiate inflammatory gene transcription in MG,
with its depletion conferring a neuroprotective homeostatic
MG state.
Transcription factors that mediate GRIP1 proinflammatory
properties in WT mice remain to be identified; however, upre-
gulation of genes encoding several nuclear receptors for which
GRIP1 is a known coactivator is notable in this regard. QuSAGE
pathway analysis revealed the upregulation of Nr4a2 (Nurr1)
and Nr4a3 (NOR-1) transcripts in myeloid cells from spinal cords
of WT EAE mice relative to GRIP1-cKO mice. Members of the
Nr4a subfamily of orphan nuclear receptors are emerging as
key regulators of inflammation, with both anti- and proin-
flammatory activities reported (Koenis et al., 2018; Pei et al.,
2006; Raveney et al., 2013; Rothe et al., 2017). They are induced
by NF-κB within 30 min of exposure to pleiotropic inflamma-
tory stimuli, including LPS, cytokines, and peptide hormones in
immune cells (myeloid, T cells) and other tissues involved in
chronic inflammation (synovial tissue, atherosclerotic lesions).
Nr4a receptors in turn control their target genes by binding
either to a specific octamer DNA sequence known as the NGFI-B
response element as monomers or to palindromic sequences
termed the Nur response element as homo- or heterodimers
and activating or repressing transcription (Kurakula et al.,
2014; Murphy and Crean, 2015; Rodrı́guez-Calvo et al., 2017).
In support of an anti-inflammatory role of these receptors,
Nur77 (encoded by Nr4a1) and Nurr1 have been linked to a
homeostatic phenotype in MV (Bonta et al., 2006; Hanna et al.,
2012; Ipseiz et al., 2014; Koenis et al., 2018; Mahajan et al.,
2015). Moreover, in glial cells, Nurr1 inhibits expression
of NF-κB–induced inflammatory neurotoxic mediators by re-
cruiting the CoREST corepressor complex to the NF-κB binding
sites (Saijo et al., 2009). On the other hand, Nurr1 was shown to
be upregulated in peripheral blood T cells of MS patients and to
drive transcription of proinflammatory Il17, Ifng, and Il2 in mice
Figure 7. GRIP1 mediates IFN-β therapeutic effect in EAE. (A) Starting on
EAE DPI10, WT mice were injected with either PBS or the indicated doses of
IFN-β i.p. daily, and clinical scores were measured daily (mean ± SEM; n = 4
for each group; Kruskal-Wallis test with Dunn’s multiple comparisons test).
**, P < 0.01. (B) Starting on DPI10, mice were injected as in A with PBS (WT =
18, KO = 13; two independent experiments) or 10,000 U of IFN-β (WT-IFN =
15, KO-IFN = 18; two independent experiments), and clinical scores were
plotted daily as mean ± SEM (Kruskal-Wallis test with Dunn’s multiple
comparisons test at DPI20). The fraction of weight lost was compared be-
tween the four groups of mice as described in Fig. 1 B (Kruskal-Wallis test
with Dunn’s multiple comparisons test). The survival distribution for each
group was plotted via Kaplan-Meier curve (Mantel-Cox test). *, P < 0.05; **,
P < 0.01. ns, nonsignificant.
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with EAE (Doi et al., 2008); it also reportedly participates in
Th17 cell maturation and controls their ability to produce IL-21
(Raveney et al., 2013). In addition, Nur77 has been shown to
promote the expression of inflammatory genes such as
MARCKS, IKBKE, and MAP3K14 in LPS-activated MV (Pei et al.,
2006), whereas Nurr1 activates matrix metalloproteinase genes
in synoviocytes (Mix et al., 2007). Thus, GRIP1 could facilitate
inflammatory gene expression in myeloid cells during EAE in
conjunction with Nurr1 and NOR-1. Importantly, retinoid X
receptor, the Nr4a heterodimeric partner, was also upregulated
in the CNS myeloid cells of our WT EAE mice.
Neuroinflammation involves functional interactions between
myeloid cells and surrounding cells of the CNS. Indeed, as-
trocytes are key players in CNS inflammation (Brambilla et al.,
2014; Rothhammer et al., 2018), and activated MG, in EAE and
MS, drive astrocyte activation and neurotoxicity (Liddelow
et al., 2017) by secreting proinflammatory cytokines and com-
plement components (Lian et al., 2016). Moreover, antigen-
presenting MG and MV mediate T cell activation through
MHC class II, and our transcriptomic data show an upregulation
of C3, C1ra, and H2-Q10 transcripts in WT myeloid cells during
EAE, raising the possibility that GRIP1 contributes to their
expression.
Ongoing studies are investigating the CNS transcriptomic cell
composition during homeostasis and disease in an effort to
identify key molecular signatures driving neuroinflammation in
MS (Butovsky et al., 2014; Hickman et al., 2013; Jordão et al.,
2019). Our scRNAseq results illustrate the complexity of this
task, given the plasticity of immune cell gene expression that is
specified not only by inflammatory signals and cell–cell inter-
actions but also by the CNS topographical subregions
(Greenhalgh et al., 2020). Our results suggest that activated
myeloid cells in EAE exist in several states with a gradient of
gene expression between these states. Furthermore, the simi-
larity of activated MV and MG makes it difficult to distinguish
these cells. Although the use of homeostatic MG markers as a
proxy to determine the identity of scRNAseq subpopulations
remains a possibility, the varying degree of MG activation leads
to expression distribution rather than distinct clusters.
GRIP1 and the type I IFN pathway in MS/EAE
GRIP1 is an established GR coregulator driving anti-inflammatory
signaling of GCs in MV and in vivo. We were surprised that its
deletion showed no impact of the therapeutic efficacy of Dex in
EAE in our system. We note, however, that the high Dex doses
chosen matched those of GCs used to treat MS patients during
flares. Hence, we cannot exclude the possibility that more
thorough titration of Dex might uncover the phenotype of the
GRIP1-cKO.
In contrast, therapeutic properties of IFN-β were clearly
abolished in our GRIP1-cKO mice. Although this finding is in-
ternally consistent with well-documented neuroprotective ef-
fects of IFN-β in MS/EAE (Bermel and Rudick, 2007; Teige et al.,
2003; Touil et al., 2006) and the role of GRIP1 in the type I IFN
pathway (Flammer et al., 2010; Reily et al., 2006), a broader
question regarding the type I IFN network in MS/EAE immu-
nopathology remains unresolved. First, although efficacious in
RRMS, IFN-β is ineffective at delaying secondary progressive
MS, a more advanced disease type developed by most RRMS
patients (Panitch et al., 2004; Zhang et al., 2015). Second, almost
half of RRMS patients do not respond to IFN-β or develop re-
sistance after several months of treatment (Bertolotto, 2004;
Huber et al., 2015). Finally, in a subset of patients with a
prominent Th17 response (as well as in Th17-induced EAE), IFN-
β is proinflammatory and exacerbates pathology (Axtell et al.,
2010; Axtell et al., 2011). Some studies linked this duality of IFN-
β actions to whether it is produced in the CNS versus the pe-
riphery (Khorooshi et al., 2015; Reder and Feng, 2014). We ob-
served an upregulation of IFN signature in the CNS of WT
relative to GRIP1-cKO mice. Indeed, gene expression analysis of
the whole brain and spinal cord and the purified spinal cord–
derived myeloid cells showed an upregulation of key type I IFN
pathway genes (Irf1, Irf7, Irf4, Oas3, ifitm1) inWTmice with more
severe disease. This finding challenges the notion that IFN-β
properties in MS/EAE are uniformly protective or that MG near
CNS lesions during EAE upregulates endogenous IFN-β pro-
duction as part of the healing process (Khorooshi et al., 2015;
Kocur et al., 2015). Although not feasible at this stage, it could be
informative to examine GRIP1 expression levels in patients with
MS as related to disease severity or response to therapy.
We envision that the ability of GRIP1 to interact with dif-
ferent IRFs is linked to the complexity of IFN pathway functions
in neuroinflammation and, indeed, to the two distinct pheno-
types of GRIP1 deletion in our EAE model. Conceivably, GRIP1
binding to IRF3/7 promotes inflammatory signaling in myeloid
cells, whereas downstream of IFNAR, the GRIP1–IRF9 interac-
tion mediates IFN-β therapy. If so, GRIP1 deletion will attenuate
IRF3/7-dependent myeloid cell–induced neuroinflammation but,
at the same time, blunt the therapeutic effect of IFN-β. Cur-
rently, a subset of nuclear receptors and IRF proteins both
represent viable candidates for enacting the unexpected proin-
flammatory function of GRIP1 in neuroinflammation.
Despite undeniable progress in dissecting immune cell
pathways that mediate MS, there is no cure for this disease, and
treatments mostly aim at alleviating symptoms. A dramatic re-
cent improvement of transcriptomic tools yielded a better un-
derstanding of CNS-resident and infiltrating cell type diversity
and their shifting activation states. This is particularly applica-
ble to MG whose transcriptional states evolve as a function of
localization, age, and disease (Prinz et al., 2019). Identifying
GRIP1 as a novel player that specifies a subset of these tran-
scription programs during neuroinflammation and IFN-β ther-




C57BL/6 mice (National Cancer Institute, Charles River Labo-
ratories) and their transgenic derivatives were maintained in
the Hospital for Special Surgery (HSS) Animal Facility in full
compliance with institutional guidelines approved by the HSS
Animal Care and Use Committee. Homozygous WT (WT/WT;
GRIP1fl/fl), LysM-WT (LysM-Cre;GRIP1wt/wt), and GRIP1-cKO
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(LysM-Cre;GRIP1fl/fl) mice (see Table S7 for key resource listing)
were generated previously (Coppo et al., 2016). For all tissue and
cell collection, mice were euthanized via CO2 inhalation.
EAE induction and treatments
Active EAE
Mice 8 to 12 wk of age were immunized s.c. at two sites on the
lower back with 100 µl (200 µl/mouse) of an emulsion con-
taining 1:1 of MOG35–55 (200 µg/mouse; Rockefeller University
Proteomics Resource Center) in PBS (Corning) + H37Ra Myco-
bacterium tuberculosis (1 mg/mouse) in CFA. Mice received PTX
(200 ng/mouse; List Biological Laboratories) i.p. on days 0 and 2.
EAE was evaluated daily by weighing the mice and scoring them
following modified Hooke Laboratories mouse EAE scoring
(each score is multiplied by 2); briefly, 0 = when picked up by
base of tail, the tail has tension and is erect; 1 = tip of tail is limp;
2 = limp tail; 3 = limp tail and hind leg inhibition; 4 = limp tail
and weakness of hind legs; 5 = limp tail and dragging of hind
legs; 6 = limp tail and complete paralysis of hind legs; 7 = limp
tail and complete paralysis of hind legs in addition to hind
quarters are flat, giving the appearance of a hump on the front
quarters of the mouse; 8 = limp tail, complete hind legs, and
partial front leg paralysis; 9 = complete hind and front legs pa-
ralysis; 10 = moribund or dead. Wet food was supplied when the
animals had paralysis of one or two hind legs, and mice were
sacrificed if they reached a score of 8.0.
Passive EAE
WT female 8- to 12-wk-old donor mice were immunized as de-
scribed for active EAE but did not receive PTX. At DPI10, spleen
and dLNs (inguinal, axillary, and brachial) were collected and
passed through a 70-µm filter (Falcon) to obtain a single-cell
suspension. Cells were incubated with 1× RBC lysis buffer (Bi-
oLegend) for 5 min at 4°C. After centrifugation (500 ×g for 5 min
at 4°C), cells were cultured in complete T cell media (5 × 106
cells/ml), DMEM (Corning) supplemented with 50 µg/ml
MOG35–55, 25 ng/ml IL-12, and 10 ng/ml IFN-γ (Thermo Fisher
Scientific). After 72 h, CD4+ T cells were collected using the
Dynabeads Untouched Mouse CD4 Cells Kit (Thermo Fisher
Scientific) and injected into recipient mice (106 cells/mouse i.p.).
PTX was injected (200 ng/mouse i.p.) at days 0, 2, and 3 after
CD4+ cell transfer. Clinical scoring and disease severity were
assessed as above.
Dex and IFN-β treatment
After active EAE was induced, mice were injected i.p. daily with
Dex (50 mg/mouse; Sigma), IFN-β (104 U/mouse; R&D Systems),
or PBS from the day symptoms started (score 2.0, usually ap-
proximately DPI10) for 10 consecutive days.
Histopathology and image analysis
Mice were sacrificed and perfused through the heart with 25 ml
of PBS, followed by 25 ml of 10% neutral buffered formalin so-
lution (Sigma). Whole spines were collected and fixed overnight
in formalin. Spinal cords were extracted from bone in 70%
ethanol and transferred to the histology core. Tissues were
paraffin embedded and sectioned, and slides were stained with
H&E or LFB for myelin. Immunohistochemistry was performed
by the Laboratory of Comparative Pathology at the Weill Cornell
Medical College using anti-CD3 antibodies for T cells and anti-
Iba1 for MG and MV.
Quantitative image analysis of spinal cord H&E slides for
inflammatory loci was performed using National Institutes of
Health ImageJ software (Schneider et al., 2012). Every slide was
divided into equally sized quadrants; the number of quadrants
positive for inflammatory pockets was counted and expressed as
a percentage of the total number of quadrants. The same strat-
egy was used to count the number of CD3+ cells per slide. Myelin
areas were quantified as the ratio of the myelinated plaque area
to the total white matter area, both measured on each section
series using ImageJ. Measurements for all three parameters
(inflammatory pockets, CD3+ cell counts, and myelinated areas)
were expressed as mean ± SD for each genotype.
All Iba1 antibody–stained images were processed using the R
package EBImage (Pau et al., 2010) as follows: (1) extracted blue
channel of the image; (2) multiplied image array by 1.55 × m/
0.43137, where m is the mean of image intensity; (3) converted
image into a negative image and filtered out pixels of intensity
>0.72; (4) applied fillHull function; and (5) identified and
masked individual objects on the image. Faithfulness of object
detection was manually reviewed. Area, perimeter, maximum
radius, minimum radius, mean ± SD of radius, center of mass on
x and y axes, elliptical eccentricity, and object angle were re-
corded for analysis. Only objects bigger than 50 pixels and
smaller than 3,000 pixels were kept for further classification. To
filter out the noncellular compartment from objects identified, a
training set, composed of 277 cells and 277 noncellular objects
randomly selected from among 1,614 manually classified and
randomly selected objects, was used to build a random tree
forest classifier (mtry = 3, ntree = 1,500; Liaw and Wiener,
2002). The classifier was validated with the rest of the manu-
ally classified objects, and overall accuracy was 93.9%. This
classifier was then used to screen out noncellular objects from all
objects identified previously. Measurements were scaled by
ranking each of them across all objects. MG activation status
classification was achieved by cutting the tree yielded by ag-
glomerative hierarchical clustering (complete-linkage method)
into three clusters. Sums of cells in each cluster were recorded
for each image. The morphology of randomly selected 20 cells
from each cluster was assessed: round = activated MG; bushy =
activating MG; and dendritic = homeostatic MG.
Isolation of CNS-infiltrating cells
Mice were sacrificed and perfused through the heart with 25 ml
of PBS using an 18-gauge needle. Spinal cords were flushed out
of the spines by inserting a 5-ml syringe needle filled with 1×
PBS, minced with dissection scissors, and incubated in 1× HBSS
containing 4,000 U/ml collagenase D (Roche) and 10 ng/ml
DNase I (Roche) for 30 min at 37°C. Enzymatic digestion was
stopped by adding 0.5 M EDTA to a 12.5 mM final concentration,
and tissue was pipetted up and down with a Pasteur pipette to
release cells. Samples were then filtered through a 70-µm mesh
and washed with PBS supplemented with 2% FBS (Atlanta Bio-
logicals) to remove collagenase D, and then pellets were purified
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using a 30%/70% Percoll density gradient (Sigma) to separate
immune cells from myelin. After collection, immune cells were
washed twice with PBS, counted, and stained for flow cytometry
(antibodies panel described below).
Antibodies and FACS analysis
Cells were suspended in 1 ml of FACS buffer (PBS with 2% FBS).
After Fc receptor blocking with antimouse CD16/32 (BioLegend),
cells were incubated with a mix of antibodies specific to analysis
at 1:200 dilution each for 20 min, and dead cell marker 7-
aminoactinomycin D (5 µl/sample) or DAPI (1 µl/sample) was
added right before acquisition on a BD FACSCanto II device. Data
were analyzed using BD FACSDiva software. Cell counts were
reported to initial cell number determined after Percoll density
gradient purification.
The antibody panel for CNS-infiltrating cells was as follows:
Alexa Fluor 488 anti-CD45, APC anti-CD3, PE anti-CD11b, PE–
cyanine 7 anti-F4/80, and 7- aminoactinomycin D (BioLegend).
The antibody panel for RNAseq was as follows: Alexa Fluor
488 anti-CD45, APC anti-CD3, PE anti-CD11b, and DAPI
(BioLegend).
Restimulation of cells in vitro
Mixed T cells and APCs from dLNs and spleens were prepared
from mice at DPI7 or DPI20, and single-cell suspensions were
made using a 70-µm cell strainer. For spleens, following RBC
lysis, single-cell suspensions were counted, resuspended at 8 ×
106 cells/ml, and restimulated overnight with 50 µg/ml MOG35–55
peptide and 1 µg/ml each of anti-CD3 and anti-CD28. Brefeldin A
(5 µg/ml; Sigma-Aldrich) was added for the last 4 h of culture, and
cytokine production from T cells was evaluated using a cytometric
bead array (CBA; BD Biosciences).
Serum cytokine measurements
Mice were sacrificed when one or more mice reached a clinical
score of 8 or higher. Blood was collected from the heart with 18-
gauge needles, centrifuged immediately to separate serum from
RBC, and flash frozen on dry ice. Cytokine levels were measured
using the BD CBA Mouse Inflammation Kit for IL-6, IL-10, MCP-
1, IFN-γ, TNF, and IL-12p70 and the Mouse Th1/Th2/Th17 Cy-
tokine Kit to quantify IL-2/TNF/IFN-γ for Th1, IL-6/IL-4/IL-10
for Th2, and IL-17A for Th17. Briefly, serum samples were diluted
following kit instructions and incubated with a mix of antibody-
conjugated beads, followed by addition of PE detection reagent.
Fluorescence levels were assessed with the FACSCanto II device,
and cytokine levels were determined by comparing the fluo-
rescence intensity of the PE reagent and reporting it to a control
standard curve for each cytokine.
Neonatal mouse MG isolation
P0 mice were decapitated; olfactory nerves were cut; and cere-
bellum, midbrain, and meninges were carefully removed under
a microscope. Meninges-free brains were pooled, washed, and
digested in 0.25% trypsin with 10 mg/ml DNase I (Roche) for
10 min at room temperature. Then, cells were homogenized
gently with a 1,000-µl pipette to break up tissue without killing
cells, filtered through a 100-µm cell strainer (BD Biosciences),
and placed into DMEM with 10% FBS in the presence of 20%
L-cell–conditionedmedia. 24 h thereafter, cells werewashed and
observed, with media changed every 3–4 d, until a large number
of MG started to appear on top of the astrocyte monolayer. At
days 14–20, cells were trypsinized, andMGwas isolated by Cd11b
microbead (Miltenyi Biotec) selection. MG were plated at a
density of 50,000 cells/cm2 in DMEM with 10% FBS and 1%
penicillin-streptomycin in flasks precoated with 0.01% poly-
L-lysine (Sigma) for a minimum of 2 h. On the next day, they
were treated as indicated in the figure legends and harvested for
RNA isolation.
Immunoblotting
8–12-wk-old mice were killed, and BMMV were generated as
described elsewhere (Chinenov et al., 2012). In brief, tibia and
femur BM was flushed and cultured in 1 g/liter glucose-
containing DMEM with 20% FBS supplemented with 20%
L-cell–conditioned media for 5 d. Adherent cells were then
scraped, plated at 2 × 107 in 150-mm plates in DMEM with 20%
FBS, and cultured overnight before harvest. Mixed glial cultures
from P0 pups were prepared as described above, and the as-
trocyte monolayer was collected after MG purification by per-
cussing the flask with a flat palmar surface. Dorsal root ganglia
were isolated from E15 pups’ spinal cords as described previ-
ously (Sleigh et al., 2016). For T cell purification, spleens were
collected and crushed, and single-cell suspensions were pre-
pared using a 70-µm cell strainer. RBC lysis was performed, and
CD4+ T cells were isolated using the Dynabeads Untouched
Mouse CD4+ Cells Kit.
Whole-cell extracts were prepared using a standard proce-
dure in radioimmunoprecipitation assay buffer (10 mM Tris-
HCl, pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 140 mM NaCl, 5%
glycerol, 0.1% Na-deoxycholate, 0.1% SDS, 1% Triton X-100).
Proteins were fractionated by SDS-PAGE and transferred to a
polyvinylidene difluoride membrane using a transfer apparatus
according to the manufacturer’s protocols (Bio-Rad Laborato-
ries). Membranes were incubated in 5% nonfat milk in TBST
(10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween 20) in the
presence of commercial primary antibodies against GRIP1
(ab10491, 1:2,000, Abcam; and 611319, 1:500, BD Biosciences) and
heat shock protein 90 (4874S, 1:2,000; Cell Signaling Technol-
ogy) at 4°C overnight, washed in TBST (three times for 5 min
each), and incubated with secondary antirabbit or antimouse
HRP conjugate (W4011 and W4021, 1:10,000; Promega) at room
temperature for 60 min. Blots were washed with TBST (three
times for 5 min each) and developed with an enhanced chemi-
luminescence system (Amersham Biosciences) according to the
manufacturer’s protocols.
RNA preparation and real-time qPCR
Total RNA was isolated from cells with the RNeasy Plus Micro
Kit (QIAGEN) or from homogenized whole brains and spinal
cords of perfused mice using TRIzol (Thermo Fisher Scientific)
extraction. RNA samples were subjected to random-primed
cDNA synthesis, and gene expression was analyzed by qPCR
with Maxima SYBR Green/ROX/2× Master Mix (Fermentas) on
the StepOne Plus Real-Time PCR System (Applied Biosystems)
Mimouna et al. Journal of Experimental Medicine 13 of 18
Transcription cofactor GRIP1 in neuroinflammation https://doi.org/10.1084/jem.20192386
using the comparative cycle threshold method. PCR primers are
listed in Table S6.
Transcriptomic analysis
Bulk RNAseq and pathway analysis
Mice were killed, and immune cells were collected from the CNS
as described above, stained (antibodies panel described below)
in PBS with 2% FBS, and sorted at the Weill Cornell Flow Cy-
tometry Core. F4/80+CD11b+CD45high and F4/80+CD11b+CD45low
sorted cells were collected in 350 µl of RLT buffer, and total RNA
was isolated using the RNeasy Plus Micro Kit. The integrity of
RNA and the quality of sequence-compatible libraries were
evaluated with the BioAnalyzer 2100 system (Agilent). RNA
was poly(A) enriched, and paired-end sequencing–compatible
RNAseq libraries were prepared by the Weill Cornell Epi-
genomics Core Facility and sequenced (HiSeq 2500; 50-bp
single-end protocol) at a depth of 22 million to 29 million
mappable reads/sample. Read quality evaluation and adapter
trimming were performed using fastp. All reads that passed
initial quality filtering were mapped to the mouse genome
(mm10), and reads in exons were counted against GENCODE
release 27 annotation with the STAR aligner (Dobin et al., 2013).
Batch correction to account for sex and day of the experiment
was performed using the surrogate variable analysis (sva)
ComBat function in R (Leek et al., 2020). Differential gene ex-
pression analysis was performed with edgeR using a likelihood
ratio test. Genes with low expression levels (<3 counts per
million in at least one group) were filtered from all downstream
analyses. Genes with unadjusted P values <0.01 and log2 fold
change >1 were considered differentially expressed. Down-
stream analyses were performed in R using a Shiny-driven vi-
sualization platform (RNAseq DRaMA) developed at the HSS
David Z. Rosensweig Genomics Research Center.
Briefly, myeloid gene expression was modeled as a batch-
corrected average of gene expression in MV (CD45high; n =
2–4) and MG (CD45low; n = 3). Differentially expressed genes as
defined above were used to perform QuSAGE pathway analysis
using the MsigDB 6.2 C2 set (curated gene sets). All gene sets
with unadjusted P values <0.01 were log fold change sorted and
visualized using RNAseq DRaMA.
scRNAseq amplification and library preparation
Myeloid cells from mice with EAE were obtained as described
in the Bulk RNAseq and pathway analysis section. F4/
80+CD11b+CD45+ cells were sorted and retrieved in PBS, and the
scRNAseq libraries were constructed using Chromium Single-
Cell 39 Reagent Kit version 3 according to the manufacturer’s
workflow (10x Genomics). Briefly, single suspensions of FACS-
sorted cells were encapsulated into emulsion droplets at a
concentration of 500 cells/µl using the Chromium Controller
(10x Genomics) for target output of ∼5,000 cells/sample. After
reverse transcription and droplet dissociation, cDNA was pu-
rified with Dynabeads and amplified by PCR (13 cycles). For
library construction, resulting cDNAs were fragmented, size
selected (450 bp) with solid-phase reversible immobilization
beads, and PCR amplified (14 cycles). The sequencing libraries
were subjected to final cleanup using solid-phase reversible
immobilization beads and evaluated on an Agilent Bioanalyzer.
The generated scRNAseq libraries were sequenced by the Weill
Cornell Genomics Core on the Illumina NovaSeq system using a
28-8-98 paired-end cycle.
scRNAseq data analysis
scRNAseq analysis was performed in R version 4.0.1 software (R
Core Team, 2019). Quality control metrics were calculated with
scater (McCarthy et al., 2017), and low-quality cells with mito-
chondrial reads exceeding replica median +1× median absolute
deviation and <250 genes per cell were filtered out. Genes were
filtered out if detected in <0.5% of all cells. Normalization was
then performed using a cell pool deconvolution method (Lun
et al., 2016). Doublet cells were predicted with scran’s double-
tCells function, and cells with the doublet score in the upper
decile were excluded from further analysis. Cell cycle phases
were assigned using scran’s cyclone function. Highly variable
genes were selected by modeling the relationships between the
gene squared coefficient of variation relationship and mean
expression values. Highly variable genes with false discovery
rate <0.1 were used for data dimensionality reduction with
principal component (PC) analysis; the top 18 PCs were selected
using jackstraw (Chung, 2020).
Replica integration was performed using fastMNN im-
plementation of a mutual nearest neighbors algorithm from the
batchelor package (Haghverdi et al., 2018) using the top 18 PCs
and the number of nearest neighbors, k = 20. The integrated PCs
were projected into two-dimensional UMAP space (Mclnnes
et al., 2018) for visualization. To further ascertain cell sub-
populations, we performed community clustering using the
Louvain algorithm (R::igraph) applied to the shared nearest
neighbor graph build using the scran::buildSNNGraph function
with the number of nearest neighbors, k = 75, in mnn-corrected
PC analysis space (18 dimensions). Cluster characteristics are
shown in Table S1. To get insight into the identity of the Louvain
clusters, we searched for cluster-specific markers using the
Wilcoxon rank-sum test (Korsunsky et al., 2019). The U statistics
of the test are proportional to receiver operating characteristic
analysis area under the curve. In pairwise comparison between
a given cluster and all other clusters (one against all), area under
the curve is interpreted as the probability of a cell from one
cluster having higher expression of a given gene than cells from
other clusters. An automated cell type assignment was per-
formed with singleR using training sets derived from the Im-
munological Genome Project database (Aran et al., 2019). In
addition, we used PanglaoDB to identify putative cell identity
and/or activation state for each individual cluster. To identify
cell type and cell activation state transitions, we performed
trajectory analysis with slingshot (Street et al., 2018) in
UMAP1–UMAP2 coordinates. Because the Louvain cluster 3 is
the only cluster heavily enriched with cell proliferation
markers, and because singleR assigns several types of stem cells
to this cluster, we assigned cluster 3 as a trajectory starting
cluster. We further excluded Louvain clusters 8 and 9 that have
a well-defined cell identity (combined T cells and neutrophils).
Trajectory-associated markers were determined by fitting a
general additive model with a locally estimated scatterplot
Mimouna et al. Journal of Experimental Medicine 14 of 18
Transcription cofactor GRIP1 in neuroinflammation https://doi.org/10.1084/jem.20192386
smoothing term for each gene to model the relationships be-
tween gene expression and pseudo-time.
Finally, we determined differentially expressed genes be-
tween WT and GRIP1-cKO mice, stratified by Louvain or singleR
clusters (Tung et al., 2017), using a pseudo-bulk approach as
implemented in the scran package (Franzén et al., 2019). Briefly,
pseudo-bulk samples were created for each Louvain cluster by
aggregating counts for all cells with the same combination of
genotype and sample (cluster 3 was excluded due to a low cell
number in this cluster in the WT). Differential expression
analysis was performed with the edgeR quasi-likelihood frame-
work using the pseudoBulkDGE function of the scran package that
allows simultaneous differential expression analysis in multiple
clusters (Table S5).
Data deposition
RNAseq of MG from WT and cKO P0 mice and of myeloid cells
from spinal cords of WT and KO mice with EAE is available in
the Gene Expression Omnibus database (GSE141721).
Online supplemental material
Fig. S1 includes additional data related to Fig. 1, showing the gene
expression profile in WT and GRIP1-cKO P0 MG in response to
LPS, LPS + Dex, or LPS + IFN-β. Fig. S2 includes additional data
related to Fig. 1 and Fig. 2, showing that EAE attenuation in
GRIP1-cKO mice is independent of Cre expression, the lack of
apparent phenotype in GRIP1-cKO at homeostasis, and our FACS
gating strategy. Fig. S3 includes additional data related to Fig. 3,
showing gene expression analysis in whole spinal cords of WT
and GRIP1-cKO mice at homeostasis and at EAE DPI20, and the
Th2 cytokine production from T cells isolated from WT and
GRIP1-cKO mice at DPI7 and DPI20 and restimulated in vitro.
Fig. S4 includes additional scRNAseq analysis related to Fig. 6.
Fig. S5 includes additional data related to Fig. 7 indicating that
Dex treatment reverses EAE similarly in WT and GRIP1-cKO
mice. Table S1, Table S2, Table S3, Table S4, and Table S5 in-
clude datasets related to Fig. 6 scRNAseq analysis. Table S6,
related to Fig. 3 A, Fig. S1 B, and Fig. S3 A, shows sequences of
PCR primers used in this study. Table S7 lists key resources used
in this study.
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Supplemental material
Figure S1. Characterization of P0 MG gene expression in vitro. (A) Gene expression in MG derived in vitro from WT and cKO P0 pups (see Materials and
methods) and treated for 2 h with 10 ng/ml LPS ± 100 nMDex or 10 ng/ml LPS ± 500 U/ml IFN-βwas profiled by RNAseq (n = 2 with multiple neonates pooled
for each experiment). Volcano plots (fold change = 2; FDR P < 0.05) show genes regulated by LPS (red) in WT (963 total; 553 upregulated) and cKO (1,403 total;
854 upregulated) overlaid with genes downregulated by Dex (teal; 163 and 460 in WT and cKO, respectively), IFN-β (green; 115 and 96 in WT and cKO,
respectively), or both (dark blue; 20 and 11 in WT and cKO, respectively). Shown in black are key inflammatory cytokines upregulated by LPS and down-
regulated by Dex as well as IFN-β. (B) Neonatal WT and cKO MG were treated for 2 h with LPS ± Dex or with IFN-β, and expression of indicated genes was
assessed by RT-qPCR with Actb used for normalization. Relative expression of GRIP1 and GRmRNA in the cKO are shown relative to that inWT (= 1; n = 4). Fold
repression by Dex = [RNA]LPS/[RNA]LPS+Dex (n = 5). Induction of ISGs by IFN-β is shown relative to untreated (= 1; n = 4). Shown are mean ± SD; two-tailed
Student’s t test; *, P < 0.05; **, P < 0.01; ****, P < 0.0005.
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Figure S2. Disease severity is independent of Cre expression, and homeostatic GRIP1-cKO mice display no apparent phenotype. (A) Clinical scores
were determined daily following EAE induction in eight WT, nine LysM WT, and seven cKO mice and plotted as mean ± SEM (Kruskal-Wallis test with Dunn’s
multiple comparisons test at DPI20). The fraction of weight lost by DPI20 was assessed in WT, LysM WT, and cKO mice as in Fig. 1 B (Kruskal-Wallis test with
Dunn’s multiple comparisons test at DPI20). Survival distribution was plotted via Kaplan-Meier curve and compared between strains as in Fig. 1 B (Mantel-Cox
test). *, P < 0.05; **, P < 0.01. ns, nonsignificant. (B) Homeostatic age-matched WT and cKO mice (n = 3) were killed, and their blood was collected by cardiac
puncture. Serum concentrations of indicated inflammatory cytokines were measured using CBA as in Fig. 1 C. Spinal cord lumbar sections from age-matched
WT and cKO mice were analyzed as in Fig. 2 A by H&E staining for inflammatory foci, LFB staining for myelin, immunohistochemistry for CD3+ T cells, and Iba-
1+ for MG and MV. Scale bar is 100 µm. FACS analysis of leukocytes isolated from spinal cords of WT or cKOmice (n = 3) is plotted as a percentage of the gated
parent population and total counts. (C) FACS gating strategy for all experiments. Cells were purified from spinal cords ofWT and GRIP1-cKOmice with EAE and
separated from myelin using Percoll gradient. From total selected cells, live (7-AAD−) cells were gated on. Of those, CD45+ cells were gated on as leukocytes
and separated into two populations: CD3+ T cells and CD11b+ cells containing B cells, myeloid cells, and natural killer cells. The myeloid cell subpopulation
expressing F4/80 was regated and divided into Cd11b+CD45low MG and Cd11b+CD45high MV. FSCA, forward-scatter area; SSCA, side-scatter area.
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Figure S3. GRIP1-cKO mice develop less spinal cord inflammation and attenuated early peripheral Th2 T cell response in vitro. (A) Spinal cords were
harvested from control (WT = 6; GRIP1-cKO = 5) and EAE DPI20 (WT = 6; GRIP1 cKO = 6) mice, and total RNA was extracted. Relative expression of the
indicated genes was evaluated by RT-qPCR, normalized to that of the Actb housekeeping gene, and expressed relative toWT control (=1; two-way ANOVA with
Tukey’s multiple comparisons test). *, P < 0.05; **, P < 0.01; ***, P < 0.005. ns, nonsignificant. (B) Spleens were collected at DPI7 (WT = 10; GRIP1-cKO = 9; two
independent experiments) and DPI20 (n = 5 each from one experiment). CD4+ T cells were isolated, then restimulated with MOG35–55 in vitro, and the indicated
Th2-secreted cytokines were quantified using CBA (unpaired two-tailed Student’s t test). *, P < 0.05; **, P < 0.01.
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Figure S4. scRNAseq of spinal cord myeloid cells from WT and GRIP1-cKO mice at EAE DPI20. (A) Bootstrapping analysis of cell densities in the
UMAP1–UMAP2 coordinates, stratified by genotypes. 2,000 cells were randomly sampled for each genotype, and the two-dimensional density matrix was
calculated for an 800 × 800 binned matrix. The sampling was performed 500 times, and the average density for each bin was computed and plotted.
(B) Automated cell cycle stage assignment for 20,376 spinal cord–derived myeloid cells. (C) singleR trajectory inference for 20,376 spinal cord–derived myeloid
cells mapped onto a UMAP plot and colored by pseudo-time. Blue and black lines represent fitted PC curves. (D) Expression of MΦmarkers in MΦ-like clusters
1 (red), 2 (blue), and 7 (light green). The color of expression profiles corresponds to Louvain clusters in Fig. 6 C. (E) Expression of homeostatic MG markers
mapped onto a UMAP plot, stratified by genotypes.
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Tables S1–S6 are provided online. Table S1 lists cell count by Louvain or singleR clusters. Table S2 lists cluster-specific markers in
Louvain clusters. Table S3 reports differential expression analysis along slingshot trajectories. Table S4 shows that Gene Ontology
proliferative categories are enriched among genes with area under the curve >0.7 from cluster 3. Table S5 reports differential
expression analysis between cKO andWT cells, stratified by Louvain clusters. Table S6 lists RT-qPCR prime sequences. Table S7 lists
key resources used in this study.
Figure S5. Dex treatment reverses EAE in WT and cKO mice. (A) WT mice were injected with PBS or the indicated amounts of Dex i.p. daily at EAE
symptom onset (DPI10), and clinical scores were determined daily as mean ± SEM (n = 4 for each group; Kruskal-Wallis test with Dunn’s multiple comparisons
test at DPI20). (B) At EAE DPI10, WT and GRIP1-cKOmice were divided into two groups that received either PBS or 50mg/kg Dex i.p. daily. Clinical scores were
measured daily as mean ± SEM (WT = 10, cKO = 4; Kruskal-Wallis test with Dunn’s multiple comparisons test at DPI20). Fraction of weight lost by DPI20 was
measured in WT and cKO mice treated as above (unpaired two-tailed Student’s t test). The survival distribution in each group plotted via Kaplan-Meier curve
was evaluated using the Mantel-Cox test as in Fig. 1 B (WT = 15, cKO = 10, WT Dex = 10, and cKO Dex = 8 mice from two independent experiments). *, P < 0.05;
**, P < 0.01; ***, P < 0.001. ns, nonsignificant.
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